Filing Flows › Pure Bioscience (PURE) › Q3 FY26 › vs Q2 FY26
Pure Bioscience (PURE) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Pure Bioscience's revenue rose $63K (+14%) from $443K in Q2 FY26 to $506K in Q3 FY26. The biggest changes: SILVERION +$400K (30×); PURE Hard Surface −$337K (-79%).
Pure Bioscience, Q3 FY26: revenue $506K (+4% year over year), operating margin -102.4%, net loss $624K, operating cash flow −$468K. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| SILVERION | $414K | $14K | $400K | 30× |
| PURE Hard Surface | $92K | $429K | −$337K | -79% |
| Revenue | $506K | $443K | $63K | +14% |
| Net loss | $624K | $785K | −$161K | -21% |
| Costs & expenses | $1.1M | $1.2M | −$98K | -8% |
| Operating costs | $1.0M | $1.1M | −$102K | -9% |
| Interest & other, net | $106K | $102K | $4K | +4% |
| Cost of revenue | $237K | $205K | $32K | +16% |
| Research & development | $79K | $74K | $5K | +7% |
| SG&A | $708K | $847K | −$139K | -16% |
| Operating cash sources | $624K | $785K | −$161K | -21% |
| Share-based compensation | $55K | $58K | −$3K | -5% |
| Working capital & other | $101K | $121K | −$20K | -17% |
| Cash used in operations | $468K | $606K | −$138K | -23% |
| Net loss absorbed | $624K | $785K | −$161K | -21% |
Questions
How much did Pure Bioscience's revenue grow quarter over quarter in Q3 FY26?
Pure Bioscience's revenue rose $63K (+14%) from $443K in Q2 FY26 to $506K in Q3 FY26.
What drove Pure Bioscience's revenue change in Q3 FY26?
SILVERION +$400K (30×); PURE Hard Surface −$337K (-79%).